Regeneron reported Q4 2024 earnings today and declared its first-ever dividend of $0.88 per quarter. Click here to know what ...

City leaders said $25 million will be raised to send CCS students to Columbus State Community College for free as part of the Columbus Promise program. More than $15 million has already been raised.

Leaders from the City of Columbus, Columbus City Schools, Columbus State Community College, the college access program I Know I Can, and the Columbus Partnership, joined by several private ...

Cemiplimab significantly reduced the risk of recurrence or death in patients with high-risk cutaneous squamous cell carcinoma (CSCC) post-surgery. Adjuvant treatment with cemiplimab (Libtayo ...

More growth potential is possible as the company pointed to positive data posted for adjuvant use of Libtayo in patients with cutaneous squamous cell carcinoma (CSCC). With that result ...

The investigation will determine whether administering low doses of THIO prior to Libtayo can enhance and prolong the immune response in patients with advanced NSCLC. This study focuses on patients ...

Under the terms of the clinical supply agreement, Immuneering will sponsor the planned studies and Regeneron will provide Libtayo. Immuneering will maintain global development and ...

in combination with Regeneron's immunotherapy drug Libtayo in patients with advanced non-small cell lung cancer (NSCLC) in its ongoing Phase 2a study. IMM-1-104 is currently in a Phase 1/2a study ...

CBSE Class 10 Science Chapter Wise Important Case Study Questions: CBSE board exams are about to get started. Well, the Class 10 students are busy finishing their syllabus, revising important ...

Under the terms of the clinical supply agreement, Immuneering will sponsor the planned studies and Regeneron will provide Libtayo. Immuneering will maintain global development and commercialization ...